Vaginal Dryness and Intimacy After Menopause: What the Shilajit Research Actually Shows

Why is this the symptom nobody brings up first?

Vaginal dryness and painful intimacy after menopause are common enough that most women who experience them are not alone in a single doctor's office. They are alone in silence about it, because it is one of the harder things to bring up, even with a partner, even with a doctor.

When it does come up, the explanation is usually short. You have vaginal atrophy, a real medical term for the thinning and drying of vaginal tissue after estrogen falls. The typical next step offered is vaginal estrogen, a hormone applied locally.

For a woman who is already cautious about hormones, or who has been told to avoid them, that leaves the real question sitting unanswered. Is there a way to address the tissue itself without adding a hormone?

What was estrogen actually doing down there?

Estrogen is not just a reproductive hormone in the abstract sense.

One signal, more than one tissue

It is the specific signal that keeps the vaginal wall thick, elastic, and supplied with blood flow, and that supports the natural lubrication response during arousal. That same hormone also maintains the tissue of the bladder lining and urethra, which is why women dealing with vaginal dryness after menopause frequently deal with recurrent bladder symptoms at the same time.

It is not two separate problems. It is one signal loss, showing up in more than one place.

Here is what that one signal was actually doing.

• Keeping the vaginal wall thick and elastic
• Maintaining blood flow to the tissue
• Supporting the natural lubrication response during arousal
• Maintaining the matching tissue in the bladder lining and urethra

What the tissue looks like once the signal drops

When estrogen falls at menopause, the tissue thins, dries, and its blood supply is reduced. Doctors call this vaginal atrophy, or more recently, genitourinary syndrome of menopause. Both are accurate terms.

What they do not explain is what actually rebuilds that tissue once the signal is gone, beyond replacing the hormone itself.

What did the direct human trial on shilajit find?

This is the part of the research that most articles on this topic never mention, because it does not exist for most ingredients marketed for this purpose.

In 2023, a triple-blind, randomized, placebo-controlled clinical trial published in Traditional Medicine Research tested oral shilajit tablets directly against sexual function in women. Forty eight women took part. Half received 200 milligrams of shilajit twice daily for 60 days, and half received a placebo.

Researchers used the Female Sexual Function Index, a validated clinical questionnaire, to measure the trial.

• Desire
• Arousal
• Lubrication
• Satisfaction
• Orgasm
• Pain

The women taking shilajit showed a significantly higher overall sexual function score than the placebo group by the end of the trial. Several individual areas of the questionnaire improved meaningfully with shilajit, though the measures specific to orgasm and pain did not show a significant difference between groups. Shilajit was well tolerated throughout, with no changes to safety biomarkers and no adverse events recorded.

Here is the honest limit, stated as clearly as we can state it. This trial was conducted in reproductive-aged women, not women who were specifically postmenopausal. It is real, direct, human evidence that oral shilajit measurably shifted sexual function scores in women. It is not, on its own, a trial proving the same result in women past menopause specifically.

Why does the mechanism still apply to a postmenopausal woman?

A single trial in a different age group is not the whole picture. Here is why the result still matters to a postmenopausal woman, based on separate research in her own population.

The human connective-tissue evidence

The tissue that needs to rebuild in vaginal atrophy is, at its core, connective tissue and blood supply. A 2016 human trial found that shilajit upregulated a cluster of 17 genes involved in building connective tissue, including several collagen genes, in adult participants after 8 weeks. A separate 2019 human trial in adult women specifically found that shilajit improved skin blood perfusion over 14 weeks and upregulated genes tied to blood vessel formation and connective tissue, directly in a female population.

The animal tissue-relaxation study

There is also a rat study worth naming honestly rather than skipping. A 2013 study found that shilajit relaxed rat corpus cavernosum tissue, the type of erectile tissue present in both male and female anatomy, through what researchers described as a parasympathetic, nerve-mediated effect. This is animal tissue research, not a human trial, and we are naming that plainly rather than letting it imply more.

Here is what the fuller picture looks like, in order.

• A 2016 human trial. Shilajit upregulated 17 connective tissue genes, collagen included
• A 2019 human trial in women specifically. Shilajit improved skin blood perfusion and blood vessel gene activity
• A 2013 animal study. Shilajit relaxed the exact tissue type involved in arousal, through a nerve-mediated effect
• The 2022 Pingali bone trial. The same estrogen-signaling mechanism rebuilt tissue elsewhere in the body

None of these facts alone proves the case for a postmenopausal woman. Together, they describe a coherent, real mechanism worth knowing about.

Does shilajit add estrogen, and how is this different from what doctors already offer?

Shilajit is not a hormone and does not add estrogen to the body. The research points toward it supporting the body's own estrogen signaling rather than replacing the hormone directly, a meaningfully different approach than vaginal estrogen therapy.

That distinction matters for a woman who has been offered vaginal estrogen and hesitated. It is not a claim that shilajit replaces that option, or that it works the same way. It is a different mechanism, one that works with the signaling and tissue-building side of the equation rather than adding a hormone locally.

Here is how the two options actually compare.

Doctors do use the term vaginal atrophy, and vaginal estrogen is a real, commonly prescribed option for it. The gap is not that the condition goes unnamed. It is that the non-hormonal, tissue-signaling mechanism behind an option like shilajit is rarely explained at all.

Is shilajit safe to take for this?

In the 2023 sexual function trial, shilajit was well tolerated, with no changes to safety biomarkers and no adverse events reported over 60 days.

Here is what that trial reported directly.

• No serious adverse events
• No changes to safety biomarkers
• Well tolerated at 200 milligrams, twice daily, for 60 days

Across every human clinical study ever conducted on shilajit, zero serious adverse events have been reported. Purity is a fair, separate question, since resin quality varies enormously between sources. Optimum shilajit comes from the Altai mountains, cold pressed and purified, third party lab tested, heavy metal free, and Prop 65 compliant in California. We are a small, family owned company out of Florida, and a real person answers when you reach out. It comes as a box of tablets, not a loose powder that loses its fulvic acid before it reaches you.

This article is educational, not medical guidance for your individual history.

Optimum Shilajit, tested in full

If you want a food-form source of the trace minerals and fulvic acid behind the research above, sourced from the Altai mountains and tested for purity on every batch, here is .

See Optimum Shilajit